Skip to main content

Specialty Pharmacy

  • FDA approves new medullary thyroid cancer drug

    SILVER SPRING, Md. — The Food and Drug Administration has approved a new drug made by Exelixis for treating thyroid cancer, the agency said.

    The FDA announced the approval of Cometriq (cabozatinib) to treat medullary thyroid cancer — a cancer that develops in cells in the thyroid gland that make calcitonin, a hormone that helps maintain a healthy level of calcium in the blood — that has spread to other parts of the body. Another drug to treat medullary thyroid cancer, AstraZeneca's Caprelsa (vandetanib), was approved last year.

  • PhRMA: More than 70 drugs, vaccines under development for HIV/AIDS

    WASHINGTON — Drug companies have made "remarkable progress" in treatment options for patients with HIV and AIDS, according to two new reports from a drug industry trade group.

  • Traditional drug spending falls, specialty spending rises, ESI report finds

    ST. LOUIS — Price inflation for the most commonly used branded drugs has been more than six times that of overall inflation for consumer goods since September 2011, according to a new report by pharmacy benefit manager Express Scripts.

  • BioPlus highlights services to hurricane-affected patient

    ALTAMONTE SPRINGS, Fla. — By the time Hurricane Sandy had finished sweeping up the East Coast, it left billions of dollars in damage and took dozens of lives.

    But it caused another dimension of hardship for some people: those living with chronic diseases.

  • Walgreens to focus on importance of HIV testing, early treatment on World AIDS Day

    DEERFIELD, Ill. — On World AIDS Day, Dec. 1, Walgreens will encourage communities to focus on the importance of HIV testing and early treatment, both services addressed through its more than 700 HIV-specialized pharmacies coast to coast, the company announced Wednesday. 

  • Novo Nordisk app designed to help hemophilia patients, families

    PRINCETON, N.J. — Novo Nordisk has launched a mobile app for hemophilia patients, the drug maker said.

    HemaGo — available for iPhone, iPad and Android devices — is designed to track hemophilia treatment, bleeding episodes and life events, helping people with the condition and their caregivers monitor the details of treatment, including medications, dosing, bleeding information and the disease's effects on life events.

  • Medication nonadherence costs drug makers $188 billion per year in U.S., report finds

    NORWALK, Conn. — When it comes to medication non-adherence, the most oft-cited statistic illustrating its effect on the healthcare system is the New England Healthcare Institute's estimate that it costs the healthcare system $290 billion per year. But a new report shows how much drug makers lose as well.

  • Fred's looks to grow through Diplomat Specialty partnership and Drug and Dollar concept pharmacy

    MEMPHIS, Tenn. — Any trickle-down of an improving economy hasn't trickled down to Fred's consumer base, Bruce Efird, Fred's CEO, told analysts Tuesday morning in discussing the discounter's third-quarter results. "During the third quarter we continue to see generally weak economic conditions throughout the Southeast which are clearly weighing heavily on our customers and influencing how they shop for their basic needs," he said. "It's more evident that things are not getting better for our core customers." 

X
This ad will auto-close in 10 seconds